Joaquin Cubiella

List of Publications by Year
in descending order

138	4,734	109321	110387
papers	citations	35 h-index	64 g-index

152	152	152	5820
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Perceived barriers and benefits in the participation in faecal occult blood test colorectal cancer screening programme. GastroenterologÃa Y HepatologÃa, 2023, 46, 185-194.	0.5	0
2	Quality of Colonoscopy Is Associated With Adenoma Detection and Postcolonoscopy Colorectal Cancer Prevention in Lynch Syndrome. Clinical Gastroenterology and Hepatology, 2022, 20, 611-621.e9.	4.4	17
3	ValidaciÃ³n al castellano del cuestionario Rawl de cribado de cÃ¡ncer colorrectal con sangre oculta en heces. GastroenterologÃa Y HepatologÃa, 2022, 45, 106-113.	0.5	2
4	Faecal immunochemical tests safely enhance rational use of resources during the assessment of suspected symptomatic colorectal cancer in primary care: systematic review and meta-analysis. Gut, 2022, 71, 950-960.	12.1	20
5	Real-time polyp detection model using convolutional neural networks. Neural Computing and Applications, 2022, 34, 10375-10396.	5.6	29
6	Risk of Colorectal Cancer and Advanced Polyps One Year After Excision of High-Risk Adenomas. Diseases of the Colon and Rectum, 2022, 65, 1112-1120.	1.3	3
7	Rawlâ€™s questionnaire Spanish validation for colorectal cancer screening with faecal occult blood testing. GastroenterologÃa Y HepatologÃa (English Edition), 2022, , .	0.1	0
8	Complicaciones postquirÃºrgicas en un programa de cribado poblacional de cÃ¡ncer colorrectal: Incidencia y factores asociados. GastroenterologÃa Y HepatologÃa, 2022, , .	0.5	1
9	Effect of the Nutraceutical Micodigest 2.0 on the Complication Rate of Colorectal Cancer Surgery With Curative Intent: Protocol for a Placebo-Controlled Double-blind Randomized Clinical Trial. JMIR Research Protocols, 2022, 11, e34292.	1.0	0
10	Faecal Immunochemical Test Impact on Prognosis of Colorectal Cancer Detected in Symptomatic Patients. Diagnostics, 2022, 12, 1013.	2.6	0
11	Closing the gap for post-colonoscopy colorectal cancer. The Lancet Gastroenterology and Hepatology, 2022, , .	8.1	1
12	A Comprehensive Metabolomics Analysis of Fecal Samples from Advanced Adenoma and Colorectal Cancer Patients. Metabolites, 2022, 12, 550.	2.9	9
13	Deep Neural Networks approaches for detecting and classifying colorectal polyps. Neurocomputing, 2021, 423, 721-734.	5.9	65
14	Optimal diagnostic accuracy of quantitative faecal immunochemical test positivity thresholds for colorectal cancer detection in primary health care: A communityâ€based cohort study. United European Gastroenterology Journal, 2021, 9, 256-267.	3.8	15
15	Gastric cancer screening in low incidence populations: Position statement of AEG, SEED and SEAP. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 67-86.	0.1	6
16	Colorectal cancer screening and diagnosis: omics-based technologies for development of a non-invasive blood-based method. Expert Review of Anticancer Therapy, 2021, 21, 723-738.	2.4	9
17	Germline and Somatic Whole-Exome Sequencing Identifies New Candidate Genes Involved in Familial Predisposition to Serrated Polyposis Syndrome. Cancers, 2021, 13, 929.	3.7	12
18	Systematic review with metaâ€analysis: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer. Alimentary Pharmacology and Therapeutics, 2021, 54, 14-23.	3.7	20

#	Article	IF	Citations
19	Quality in diagnostic upper gastrointestinal endoscopy for the detection and surveillance of gastric cancer precursor lesions: Position paper of AEG, SEED and SEAP. GastroenterologÃa Y HepatologÃa (English Edition), 2021, 44, 448-464.	0.1	0
20	Documento de posicionamiento de la AEG, la SEED y la SEAP sobre calidad de la endoscopia digestiva alta para la detecciÃ³n y vigilancia de las lesiones precursoras de cÃ¡ncer gÃ¡strico. GastroenterologÃa Y HepatologÃa, 2021, 44, 448-464.	0.5	9
21	Editorial: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancerâ€"Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 506-507.	3.7	2
22	Overtreatment in nonmalignant lesions detected in a colorectal cancer screening program: a retrospective cohort study. BMC Cancer, 2021, 21, 869.	2.6	4
23	Polyprev: Randomized, Multicenter, Controlled Trial Comparing Fecal Immunochemical Test with Endoscopic Surveillance after Advanced Adenoma Resection in Colorectal Cancer Screening Programs: A Study Protocol. Diagnostics, 2021, 11, 1520.	2.6	7
24	Documento de posicionamiento de la AEG, la SEED y la SEAP sobre cribado de cÃ¡ncer gÃ¡strico en poblaciones con baja incidencia. GastroenterologÃa Y HepatologÃa, 2021, 44, 67-86.	0.5	21
25	Impact of a colorectal cancer screening program implantation on delays and prognosis of non-screening detected colorectal cancer. World Journal of Gastroenterology, 2021, 27, 6689-6700.	3.3	4
26	Faecal immunochemical test outside colorectal cancer screening?. World Journal of Gastroenterology, 2021, 27, 6415-6429.	3.3	9
27	Faecal Diagnostic Biomarkers for Colorectal Cancer. Cancers, 2021, 13, 5568.	3.7	7
28	Interplay between Genome, Metabolome and Microbiome in Colorectal Cancer. Cancers, 2021, 13, 6216.	3.7	16
29	Variation in Colonoscopy Performance Measures According to Procedure Indication. Clinical Gastroenterology and Hepatology, 2020, 18, 1216-1223.e2.	4.4	22
30	White-Light Endoscopy Is Adequate for Lynch Syndrome Surveillance in a Randomized and Noninferiority Study. Gastroenterology, 2020, 158, 895-904.e1.	1.3	27
31	Clinical and Pathological Characterization of Lynch-Like Syndrome. Clinical Gastroenterology and Hepatology, 2020, 18, 368-374.e1.	4.4	23
32	Using linkage studies combined with wholeâ€exome sequencing to identify novel candidate genes for familial colorectal cancer. International Journal of Cancer, 2020, 146, 1568-1577.	5.1	8
33	CA19-9 capability as predictor of pancreatic cancer resectability in a Spanish cohort. Molecular Biology Reports, 2020, 47, 1583-1588.	2.3	13
34	Validation of miR-1228-3p as Housekeeping for MicroRNA Analysis in Liquid Biopsies from Colorectal Cancer Patients. Biomolecules, 2020, 10, 16.	4.0	9
35	Predictive Value of Carcinoembryonic Antigen in Symptomatic Patients without Colorectal Cancer: A Post-Hoc Analysis within the COLONPREDICT Cohort. Diagnostics, 2020, 10, 1036.	2.6	1
36	Not so FAST. Commentary on the article â€œAppraisal of the faecal haemoglobin, age and sex test (FAST) score in assessment of patients with lower bowel symptoms: an observational studyâ€• BMC Gastroenterology, 2020, 20, 231.	2.0	2

#	Article	IF	Citations
37	Colorectal Cancer Survival in 50- to 69-Year-Olds after Introducing the Faecal Immunochemical Test. Cancers, 2020, 12, 2412.	3.7	9
38	Risk of Cancer in Family Members of Patients with Lynch-Like Syndrome. Cancers, 2020, 12, 2225.	3.7	6
39	Integrative Analysis of Fecal Metagenomics and Metabolomics in Colorectal Cancer. Cancers, 2020, 12, 1142.	3.7	53
40	Impact of the faecal immunochemical test on colorectal cancer survival. BMC Cancer, 2020, 20, 616.	2.6	16
41	Value of Serum NEUROG1 Methylation for the Detection of Advanced Adenomas and Colorectal Cancer. Diagnostics, 2020, 10, 437.	2.6	7
42	Principles for Evaluation of Surveillance After Removal of Colorectal Polyps: Recommendations From the World Endoscopy Organization. Gastroenterology, 2020, 158, 1529-1533.e4.	1.3	11
43	Colorectal cancer genetic variants are also associated with serrated polyposis syndrome susceptibility. Journal of Medical Genetics, 2020, 57, 677-682.	3.2	11
44	Increased Th17-Related Cytokine Serum Levels in Patients With Multiple Polyps of Unexplained Origin. Clinical and Translational Gastroenterology, 2020, 11, e00143.	2.5	1
45	Resumption of endoscopy in the Galician colorectal cancer screening programme after the COVID-19 lock down: patient safety results. Revista Espanola De Enfermedades Digestivas, 2020, 113, 119-121.	0.3	6
46	pT1 Colorectal Cancer Detected in a Colorectal Cancer Mass Screening Program: Treatment and Factors Associated with Residual and Extraluminal Disease. Cancers, 2020, 12, 2530.	3.7	8
47	Risk of gastrointestinal cancer in a symptomatic cohort after a complete colonoscopy: Role of faecal immunochemical test. World Journal of Gastroenterology, 2020, 26, 70-85.	3.3	8
48	High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome. Endoscopy, 2019, 51, 142-151.	1.8	26
49	Reduction of faecal immunochemical test falseâ€positive results using a signature based on faecal bacterial markers. Alimentary Pharmacology and Therapeutics, 2019, 49, 1410-1420.	3.7	12
50	Endoscopic surveillance after colonic polyps and colorrectal cancer resection. 2018 update. GastroenterologÃa Y HepatologÃa (English Edition), 2019, 42, 188-201.	0.1	1
51	Integrated Analysis of Germline and Tumor DNA Identifies New Candidate Genes Involved in Familial Colorectal Cancer. Cancers, 2019, 11, 362.	3.7	16
52	Efecto de la demora atribuible al sistema sanitario en el pronÃ³stico del cÃ¡ncer colorrectal. GastroenterologÃa Y HepatologÃa, 2019, 42, 527-533.	0.5	14
53	Plasma MicroRNA Signature Validation for Early Detection of Colorectal Cancer. Clinical and Translational Gastroenterology, 2019, 10, e00003.	2.5	53
54	The effect of delay on the prognosis of colorectal cancer. GastroenterologÃa Y HepatologÃa (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	0

#	Article	IF	Citations
55	Identification of a Novel Candidate Gene for Serrated Polyposis Syndrome Germline Predisposition by Performing Linkage Analysis Combined With Whole-Exome Sequencing. Clinical and Translational Gastroenterology, 2019, 10, e00100.	2.5	5
56	Vigilancia tras resecciÃ³n de pÃ³lipos de colon y de cÃ¡ncer colorrectal. ActualizaciÃ³n 2018. GastroenterologÃa Y HepatologÃa, 2019, 42, 188-201.	0.5	21
57	Accuracy of the Narrow-Band Imaging International Colorectal Endoscopic Classification System in Identification of Deep Invasion in Colorectal Polyps. Gastroenterology, 2019, 156, 75-87.	1.3	75
58	High-risk symptoms and quantitative faecal immunochemical test accuracy: Systematic review and meta-analysis. World Journal of Gastroenterology, 2019, 25, 2383-2401.	3.3	38
59	Rentabilidad terapÃ©utica de la centralizaciÃ³n de la evaluaciÃ³n y tratamiento de pÃ³lipos difÃciles. GastroenterologÃa Y HepatologÃa, 2019, 42, 648-649.	0.5	0
60	Psychological impact of multigene cancer panel testing in patients with a clinical suspicion of hereditary cancer across Spain. Psycho-Oncology, 2018, 27, 1530-1537.	2.3	30
61	Effect of aspirin on the diagnostic accuracy of the faecal immunochemical test for colorectal advanced neoplasia. United European Gastroenterology Journal, 2018, 6, 123-130.	3.8	9
62	Rare germline copy number variants in colorectal cancer predisposition characterized by exome sequencing analysis. Journal of Genetics and Genomics, 2018, 45, 41-45.	3.9	11
63	Importance of endoscopist quality metrics for findings at surveillance colonoscopy: The detectionâ€surveillance paradox. United European Gastroenterology Journal, 2018, 6, 622-629.	3.8	16
64	Detection of serrated lesions in proximal colon by simulated sigmoidoscopy vs faecal immunochemical testing in a multicentre, pragmatic, randomised controlled trial. United European Gastroenterology Journal, 2018, 6, 1527-1537.	3.8	7
65	Clinical practice guideline. Diagnosis and prevention of colorectal cancer. 2018 Update. GastroenterologÃa Y HepatologÃa (English Edition), 2018, 41, 585-596.	0.1	18
66	GuÃa de prÃ¡ctica clÃnica. DiagnÃ³stico y prevenciÃ³n del cÃ¡ncer colorrectal. ActualizaciÃ³n 2018. GastroenterologÃa Y HepatologÃa, 2018, 41, 585-596.	0.5	81
67	Symptom or faecal immunochemical test based referral criteria for colorectal cancer detection in symptomatic patients: a diagnostic tests study. BMC Gastroenterology, 2018, 18, 155.	2.0	28
68	Targeted UPLC-MS Metabolic Analysis of Human Faeces Reveals Novel Low-Invasive Candidate Markers for Colorectal Cancer. Cancers, 2018, 10, 300.	3.7	18
69	Plasma miRNAs signature validation for early detection of colorectal cancer. Annals of Oncology, 2018, 29, v106.	1.2	1
70	A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples. Clinical Epigenetics, 2018, 10, 53.	4.1	44
71	The fecal hemoglobin concentration, age and sex test score: Development and external validation of a simple prediction tool for colorectal cancer detection in symptomatic patients. International Journal of Cancer, 2017, 140, 2201-2211.	5.1	61
72	Increased Risk of Colorectal Cancer in Patients With Multiple Serrated Polyps and Their First-Degree Relatives. Gastroenterology, 2017, 153, 106-112.e2.	1.3	28

#	Article	IF	Citations
73	Annual Fecal Immunochemical Testing is as Effective as Colonoscopy Every 5 Years for Familial Colorectal Cancer Screening. Gastroenterology, 2017, 152, S542.	1.3	3
74	Correlation between adenoma detection rate in colonoscopyâ€•and fecal immunochemical testingâ€•based colorectal cancer screening programs. United European Gastroenterology Journal, 2017, 5, 255-260.	3.8	46
75	Faecal immunochemical tests (FIT) can help to rule out colorectal cancer in patients presenting in primary care with lower abdominal symptoms: a systematic review conducted to inform new NICE DG30 diagnostic guidance. BMC Medicine, 2017, 15, 189.	5.5	86
76	POLEandPOLD1screening in 155 patients with multiple polyps and early-onset colorectal cancer. Oncotarget, 2017, 8, 26732-26743.	1.8	40
77	Risk of Advanced Neoplasia in First-Degree Relatives with Colorectal Cancer: A Large Multicenter Cross-Sectional Study. PLoS Medicine, 2016, 13, e1002008.	8.4	20
78	Evaluation of serum nucleoside diphosphate kinase A for the detection of colorectal cancer. Scientific Reports, 2016, 6, 26703.	3.3	12
79	A Scoring System to Determine Risk of Delayed Bleeding After Endoscopic Mucosal Resection of Large Colorectal Lesions. Clinical Gastroenterology and Hepatology, 2016, 14, 1140-1147.	4.4	86
80	Mo1685 Rate of Detection of Serrated Lesions in Proximal Colon by Simulated Sigmoidoscopy: Comparison With Colonoscopy and Faecal Immunochemical Testing in a Multicentre, Pragmatic, Randomised Controlled Trial. Gastroenterology, 2016, 150, S750-S751.	1.3	1
81	Su1673 Importance of the Endoscopist Quality Metrics on the Findings at Surveillance Colonoscopy. The Detection-Surveillance Paradox. Gastrointestinal Endoscopy, 2016, 83, AB389.	1.0	1
82	The Fanconi anemia DNA damage repair pathway in the spotlight for germline predisposition to colorectal cancer. European Journal of Human Genetics, 2016, 24, 1501-1505.	2.8	59
83	Development and external validation of a faecal immunochemical test-based prediction model for colorectal cancer detection in symptomatic patients. BMC Medicine, 2016, 14, 128.	5.5	56
84	Incidence of advanced neoplasia during surveillance in high- and intermediate-risk groups of the European colorectal cancer screening guidelines. Endoscopy, 2016, 48, 995-1002.	1.8	21
85	Adherence to Treatment in Hypertension. Advances in Experimental Medicine and Biology, 2016, 956, 129-147.	1.6	20
86	Risk prediction models for colorectal cancer in people with symptoms: a systematic review. BMC Gastroenterology, 2016, 16, 63.	2.0	54
87	1065 Incidence of Colonic Neoplasia in Patients With Serrated Polyposis Syndrome Who Undergo Endoscopic Surveillance: A Multicenter Study. Gastroenterology, 2016, 150, S210.	1.3	0
88	Endoscopist characteristics that influence the quality of colonoscopy. Endoscopy, 2016, 48, 241-247.	1.8	42
89	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease, 2016, 48, 542-551.	0.9	23
90	Colorectal cancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut, 2016, 65, 1829-1837.	12.1	93

#	Article	IF	Citations
91	Serum matrix metalloproteinase-9 in colorectal cancer family-risk population screening. Scientific Reports, 2015, 5, 13030.	3.3	19
92	Colorectal cancer in a second round after a negative faecal immunochemical test. European Journal of Gastroenterology and Hepatology, 2015, 27, 813-818.	1.6	7
93	Colorectal cancer diagnosis: Pitfalls and opportunities. World Journal of Gastrointestinal Oncology, 2015, 7, 422.	2.0	91
94	Endoscopic surveillance in patients with multiple (10â€“100) colorectal polyps. Endoscopy, 2015, 48, 56-61.	1.8	1
95	Diagnostic Performance of Fecal Immunochemical Test and Sigmoidoscopy for Advanced Right-Sided Colorectal Neoplasms. Digestive Diseases and Sciences, 2015, 60, 1424-1432.	2.3	11
96	332 Delayed Bleeding Risk Score for Colorectal Endoscopic Mucosal Resection. Gastrointestinal Endoscopy, 2015, 81, AB135-AB136.	1.0	2
97	Serum sCD26 for colorectal cancer screening in family-risk individuals: comparison with faecal immunochemical test. British Journal of Cancer, 2015, 112, 375-381.	6.4	21
98	Prevalence and Characteristics of MUTYH-Associated Polyposis in Patients with Multiple Adenomatous and Serrated Polyps. Clinical Cancer Research, 2014, 20, 1158-1168.	7.0	57
99	Effect of oral anticoagulants on the outcome of faecal immunochemical test. British Journal of Cancer, 2014, 110, 1334-1337.	6.4	30
100	Diagnostic accuracy of fecal immunochemical test in averageâ€•and familialâ€•risk colorectal cancer screening. United European Gastroenterology Journal, 2014, 2, 522-529.	3.8	19
101	Fecal immunochemical test accuracy in familial risk colorectal cancer screening. International Journal of Cancer, 2014, 134, 367-375.	5.1	28
102	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. Clinical Gastroenterology and Hepatology, 2014, 12, 1708-1716.e4.	4.4	13
103	High incidence of large deletions in the PMS2 gene in Spanish Lynch syndrome families. Clinical Genetics, 2014, 85, 583-588.	2.0	5
104	Diagnostic accuracy of the faecal immunochemical test for colorectal cancer in symptomatic patients: comparison with <scp>NICE</scp> and <scp>SIGN</scp> referral criteria. Colorectal Disease, 2014, 16, O273-82.	1.4	73
105	Participation and detection rates by age and sex for colonoscopy versus fecal immunochemical testing in colorectal cancer screening. Cancer Causes and Control, 2014, 25, 985-997.	1.8	31
106	Characteristics of Adenomas Detected by Fecal Immunochemical Test in Colorectal Cancer Screening. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1884-1892.	2.5	19
107	Fecal immunochemical test accuracy in average-risk colorectal cancer screening. World Journal of Gastroenterology, 2014, 20, 1038.	3.3	54
108	Clinical Subtypes and Molecular Characteristics of Serrated Polyposis Syndrome. Clinical Gastroenterology and Hepatology, 2013, 11, 705-711.	4.4	36

#	Article	IF	Citations
109	Effect of Aspirin and Antiplatelet Drugs on the Outcome of the Fecal Immunochemical Test. Mayo Clinic Proceedings, 2013, 88, 683-689.	3.0	24
110	Modifiable endoscopic factors that influence the adenoma detection rate in colorectal cancer screening colonoscopies. Gastrointestinal Endoscopy, 2013, 77, 381-389.e1.	1.0	125
111	Risk of Cancer in Cases of Suspected Lynch Syndrome Without Germline Mutation. Gastroenterology, 2013, 144, 926-932.e1.	1.3	189
112	Relationship of colonoscopy-detected serrated polyps with synchronous advanced neoplasia in average-risk individuals. Gastrointestinal Endoscopy, 2013, 78, 333-341.e1.	1.0	62
113	Genetic susceptibility variants associated with colorectal cancer prognosis. Carcinogenesis, 2013, 34, 2286-2291.	2.8	18
114	Risk of Advanced Proximal Neoplasms According to Distal Colorectal Findings: Comparison of Sigmoidoscopy-Based Strategies. Journal of the National Cancer Institute, 2013, 105, 878-886.	6.3	25
115	Factors related to length of hospital admission in mild interstitial acute pancreatitis. Revista Espanola De Enfermedades Digestivas, 2013, 105, 84-92.	0.3	32
116	Evaluation of the implementation of Galician Health Service indications and priority levels for colonoscopy in symptomatic patients: prospective, cross-sectional study. Revista Espanola De Enfermedades Digestivas, 2013, 105, 600-608.	0.3	11
117	Meta-Analysis of Mismatch Repair Polymorphisms within the Cogent Consortium for Colorectal Cancer Susceptibility. PLoS ONE, 2013, 8, e72091.	2.5	19
118	Clinical practice Guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy, 2012, 44, 444-451.	1.8	131
119	Colonoscopy versus Fecal Immunochemical Testing in Colorectal-Cancer Screening. New England Journal of Medicine, 2012, 366, 697-706.	27.0	763
120	COGENT (COlorectal cancer GENeTics) revisited. Mutagenesis, 2012, 27, 143-151.	2.6	27
121	Factors Associated With Intolerance After Refeeding in Mild Acute Pancreatitis. Pancreas, 2012, 41, 1325-1330.	1.1	16
122	Immunohistochemical alterations in invasive adenocarcinoma in endoscopically resected adenoma and factors associated with risk of residual or recurrent disease. Colorectal Disease, 2012, 14, e587-94.	1.4	3
123	Factors associated with complete endoscopic resection of an invasive adenocarcinoma in a colorectal adenoma. Revista Espanola De Enfermedades Digestivas, 2012, 104, 524-529.	0.3	3
124	Clinical and Molecular Features of the Hyperplastic Polyposis Syndrome. Gastroenterology, 2011, 140, S-260.	1.3	1
125	5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients With CpG Island Methylator Phenotype Colorectal Cancer. Gastroenterology, 2011, 140, 1174-1181.	1.3	185
126	Case-control study for colorectal cancer genetic susceptibility in EPICOLON: previously identified variants and mucins. BMC Cancer, 2011, 11, 339.	2.6	38

#	Article	IF	Citations
127	Risk factors associated with the development of ischemic colitis. World Journal of Gastroenterology, 2010, 16, 4564.	3.3	57
128	Susceptibility Genetic Variants Associated With Colorectal Cancer Risk Correlate With Cancer Phenotype. Gastroenterology, 2010, 139, 788-796.e6.	1.3	47
129	Colorectal cancer prognosis twenty years later. World Journal of Gastroenterology, 2010, 16, 862-7.	3.3	28
130	The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. European Journal of Cancer, 2009, 45, 365-373.	2.8	179
131	Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients. Journal of Medical Genetics, 2008, 45, 557-563.	3.2	61
132	Clinical Performance of Original and Revised Bethesda Guidelines for the Identification of MSH2/MLH1 Gene Carriers in Patients with Newly Diagnosed Colorectal Cancer: Proposal of a New and Simpler Set of Recommendations. American Journal of Gastroenterology, 2006, 101, 1104-1111.	0.4	36
133	Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut, 2006, 55, 848-855.	12.1	199
134	Sedation at Endoscopic Units in Galicia: results of the "Sociedad Gallega de PatologÃa Digestiva" inquiry. Revista Espanola De Enfermedades Digestivas, 2005, 97, 24-37.	0.3	3
135	AnÃ¡lisis del curso clÃnico de la pancreatitis aguda hipertrigliceridÃ©mica y su comparaciÃ³n con el de la litiÃ¡sica. Medicina ClÃnica, 2004, 123, 567-570.	0.6	7
136	RetinopatÃa de Purtscher: complicaciÃ³n infrecuente de la pancreatitis aguda no alcohÃ³lica. GastroenterologÃa Y HepatologÃa, 2003, 26, 541-544.	0.5	1
137	Prognostic Factors in Nonresectable Pancreatic Adenocarcinoma: A Rationale to Design Therapeutic Trials. American Journal of Gastroenterology, 1999, 94, 1271-1278.	0.4	54
138	Post-polypectomy surveillance: walking in the fog. Endoscopy, 0, , .	1.8	0